secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2021-09-17T23:59:59+00:00
Accession:  0001104659-21-116945
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q2 revenue up 38% to $7.1M, net loss widens to $4.4M; guides FY2021 revenue ~$30M
--------------------------------------------------------------------------------

- Revenue $7.1M (+38% YoY); cell therapy ex-SPL $4.8M (+59%), drug discovery $1.8M (+60%).
- Net loss $4.4M vs $3.0M; operating expenses $10.7M (+43%) on higher comp and professional costs.
- Signed two new SPL agreements with Celularity and Sana Biotechnology for cell therapy platform.
- Completed US IPO on Nasdaq raising $201.8M gross proceeds; cash $73.4M at June 30 pre-IPO.
- Preliminary FY2021 revenue guidance of approximately $30M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465921116945/0001104659-21-116945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465921116945/tm2127942d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-116945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer